Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Roxadustat on Cardiometabolism
2023-508183-29-00Phase 4Authorised
- Sponsor
- Pohjois-Pohjanmaan hyvinvointialue
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in cardiac morbidity and cardiometabolic risk (CMR) comparing Evrenzo (roxadustat) with Placebo (2 arms). Primary endpoint: Plasma total cholesterol levels. Planned start Apr 2024; status: authorised.
02
Drugs
roxadustat
03
Conditions
cardiac morbiditycardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2023-508183-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508183-29-00.